Therapeutic Interchange Evaluation of HMG-CoA Reductase Inhibitors in Patients with Dyslipidemia
碩士 === 臺北醫學大學 === 藥學系 === 94 === Objective: Therapeutic interchange of HMG-CoA reductase inhibitors was implemented since June 6th, 2005. Atorvastatin (Lipitor®), simvastatin (Zocor®), pravastatin (Mevalotin®) and fluvastatin (Lescol®) were substituted with simvastatin (Zolotin®) and atorvastatin (L...
Main Authors: | Lin, Hong-Yun, 林虹芸 |
---|---|
Other Authors: | 廖嘉鴻 |
Format: | Others |
Language: | zh-TW |
Published: |
2006
|
Online Access: | http://ndltd.ncl.edu.tw/handle/62140259769820182115 |
Similar Items
-
Pleiotropic effects of the HMG-CoA reductase inhibitors
by: Mihos CG, et al.
Published: (2011-04-01) -
The discovery and development of HMG-CoA reductase inhibitors.
by: A Endo
Published: (1992-11-01) -
Butyrate and HMG-CoA reductase inhibitors in ulcerative colitis
by: McKay, Damian
Published: (2010) -
HMG-CoA reductase kinase: measurement of activity by methods that preclude interference by inhibitors of HMG-CoA reductase activity or by mevalonate kinase.
by: H J Harwood, Jr, et al.
Published: (1982-07-01) -
MTD–CoMSIA modelling of HMG-CoA reductase inhibitors
by: DANIEL M. DUDA-SEIMAN, et al.
Published: (2011-01-01)